Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 19-31

  Gore, Mugdha ^a   Tai, Kei Sing ^a   Chandran, Arthi ^b   Zlateva, Gergana ^b   Leslie, Douglas ^c  

^a Avalon Health Solutions Inc   (United States)

^b PFIZER INC   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Comorbidity; Duloxetine; Fibromyalgia; Pregabalin; Treatment patterns

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DULOXETINE; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; SALICYLIC ACID DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ANXIETY; ARTHROPATHY; ARTICLE; BACKACHE; BIPOLAR DISORDER; CARPAL TUNNEL SYNDROME; CAUSALGIA; CEREBROVASCULAR DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEPRESSION; DUODENITIS; FACE PAIN; FEMALE; FIBROMYALGIA; FOLLOW UP; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENERALIZED ANXIETY DISORDER; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; IRRITABLE COLON; ISCHEMIC HEART DISEASE; LOW BACK PAIN; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; NECK PAIN; OBESITY; OUTPATIENT CARE; PANIC; PERIPHERAL VASCULAR DISEASE; PHANTOM PAIN; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PREVALENCE; PROPENSITY SCORE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SLEEP APNEA SYNDROME; THORAX PAIN; TRIGEMINUS NEURALGIA;

ADOLESCENT; ADULT; AGED; ANALGESICS; COMORBIDITY; DATABASES, FACTUAL; DRUG THERAPY; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOPHENES; UNITED STATES; YOUNG ADULT;

EID: 84856058020     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.629262     Document Type: Article

References (42)

1. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
2. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
3. Lawrence RC, Felson DT, Helmick CG, et al. National arthritis data workgroup. estimates of the prevalence of arthritis and other rheumatic conditions in the united states. part ii. Arthritis Rheum 2008;58:26-35
4. Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain 1993; 1:137-48 (Pubitemid 23323898)
5. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
6. Wolfe F, Smythe HA, Yunus MB, et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72 (Pubitemid 20098653)
7. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10
8. Berger A, Sadosky A, Dukes EM, et al. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care 2010;16(5 Suppl):S126-37
9. White L, Birnbaum H, Kaltenboeck A, et al. Medical care and aps-guideline-related prescription drug use in newly diagnosed and established fibromyalgia patients. J Pain 2008;9:16
10. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508 (Pubitemid 47228612)
11. Berger A, Martin S, Dukes E, et al. Patterns of pain-related pharmacotherapy in patients with fibromyalgia. Manag Care Interface 2008;20:30-8
12. Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in germany. Curr Med Res Opin 2008;24:2489-99
13. Gore M, Sadosky A, Zlateva G, et al. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care 2010;16:144-53
14. Gore M, Sadosky AB, Zlateva G, et al. Clinical characteristics, pharmacother-apy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract 2009;9:363-74
15. Nampiaparampil DE, Shmerling RH. A review of fibromyalgia. Am J Manag Care 2004;10:794-800 (Pubitemid 39518524)
16. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
17. Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004;31:1621-9 (Pubitemid 39006646)
18. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on international classification of diseases, 9th revision codes. J Clin Rheumatol 2006;12:124-8 (Pubitemid 44314970)
19. Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006;54:177-83 (Pubitemid 43122200)
20. Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010; 26:284-90
21. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemi-ological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25 (Pubitemid 36666360)
22. Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11:117
23. Wassem R, Hendrix TJ. Direct and indirect costs of fibromyalgia to patients and their families. J Orthop Nurs 2003;7:26-32 (Pubitemid 36267357)
24. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multi-center study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70 (Pubitemid 27426148)
25. Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med 2009; 51:1384-93
26. White KP, Speechley M, Harth M, et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in london, ontario: the london fibromyalgia epidemiology study. Arthritis Rheum 1999;42:76-83 (Pubitemid 29042573)
27. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999; 74:385-98
28. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002;4:299-305
29. Burckhardt C, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children (Clinical practice guideline, no. 4). Glenview, IL: American Pain Society, 2005
30. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41 (Pubitemid 351498437)
31. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95 (Pubitemid 39491924)
32. Lyrica package insert. New York, NY: Pfizer Inc, 2007
33. Cymbalta package insert. Indianapolis, IN: Eli Lilly & Co., 2008
34. Savella package insert. New York, NY: Forest Pharmaceuticals, Inc., 2009
35. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of dulox-etine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010; 11:505-21
36. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromy-algia symptoms: how study designs can affect placebo factors. Pain 2008;136:232-4
37. D'Agostino Jr. RB, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81 (Pubitemid 28466823)
38. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
39. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83 (Pubitemid 17055592)
40. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008;4:605-14
41. Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract 2011;11:217-29
42. Zhao Y, Sun P, Sun S, et al. Comparison of dosing patterns between fibro-myalgia patients with high versus low duloxetine or pregabalin compliance. Value Health 2010;13:311